GreenGuru Pulse
What changed. What did not. What we are watching.
A calm patient briefing built from official and primary sources. Where a named organisation’s first-party service data adds useful context, Pulse labels it separately and never turns that sample into a national statistic.
Checking the local visit marker…
Research & World Change
Meaningful developments, not a cannabis news feed.
GreenGuru selects a small number of original studies and official access changes, includes negative and uncertain findings, and keeps limitations visible. Nothing appears here simply because it is new or positive.
A broad review finds benefits vary by condition and certainty remains limited
Finding
The overview reported low-to-moderate certainty evidence of benefit for some conditions, including chronic pain, multiple sclerosis and chemotherapy-related nausea and vomiting. It did not find one uniform effect across products, conditions or outcomes.
- Evidence strength
- Moderate
- Evidence type
- Human clinical evidence
What this means for patients
This supports discussing a specific medicine and indication, not assuming that all cannabis-derived products work in the same way or for every condition.
Study limitations
- This is an overview of existing reviews, so it inherits limitations and overlap in the underlying trials.
- Products, doses, routes and conditions differed substantially.
- A broad overview cannot decide whether a particular medicine is suitable for an individual patient.
Small Phase II trial reports a modest reduction in spinal-cord-injury neuropathic pain
Finding
In 38 analysed participants, high-dose oral CBD reduced self-reported pain intensity by a modest amount compared with placebo. Most secondary outcomes were unchanged, and adverse events were reported more often during CBD than placebo treatment, although nearly all were minor.
- Evidence strength
- Emerging
- Evidence type
- Human clinical evidence
What this means for patients
This is a signal worth following, not proof that CBD will relieve neuropathic pain generally. The dose was high and the result should be tested in larger trials before changing care.
Study limitations
- Only 38 participants were included in the primary analysis.
- Participants used other medicines, so interactions may have influenced outcomes.
- The crossover design had detectable residual CBD after washout, and many participants correctly identified placebo.
- The findings concern neuropathic pain after spinal cord injury and should not be generalised to other pain conditions.
Review finds little support for routine cannabinoid treatment across most mental-health conditions
Finding
The review found some condition-specific signals, but evidence quality was generally low and no significant benefit was found for several conditions including anxiety and post-traumatic stress disorder. Cannabinoids were associated with more all-cause adverse events than control treatment.
- Evidence strength
- Early
- Evidence type
- Human clinical evidence
What this means for patients
A prescription or product should not be assumed to treat a mental-health condition simply because it contains a cannabinoid. Evidence differs by condition and product, and established care should not be replaced without clinical advice.
Study limitations
- The review combined different cannabinoids, doses and diagnoses.
- Many condition-specific estimates were based on small or sparse trials.
- A pooled association does not show that every product causes the same benefit or harm.
France extends treatment continuity for patients already in its medical-cannabis experiment
- What changed
- France extended exceptional coverage and supply arrangements to 31 March 2026 for patients who were already receiving treatment when the experiment ended in December 2024.
- Who it affects
- Patients already included in the French experiment and still receiving treatment, plus their prescribers and dispensing pharmacies.
- Why it matters
- The decision protects continuity for the existing cohort while the permanent framework is considered. It does not reopen the experiment to new patients or create general access.
Germany moves medical cannabis into a separate prescribing framework
- What changed
- Germany removed medical cannabis covered by the new framework from the narcotics schedules and moved it into the Medical Cannabis Act. It remains prescription-only and pharmacy-dispensed.
- Who it affects
- Patients, doctors, pharmacies, insurers and licensed medical-cannabis suppliers in Germany.
- Why it matters
- The prescribing route changed, but the reform did not turn medical cannabis into an over-the-counter product or guarantee reimbursement. Clinical standards and insurer rules still apply.
This is a deliberately small, human-curated intelligence stream. A source monitor may identify candidates later, but it must never publish or rewrite a patient-facing item automatically. Current release: curated. Automatic publication: off.
Today on GreenGuru
The three items worth understanding first.
“Checked today” means the source was reviewed. It does not mean the underlying rule or data changed today.
Medical cannabis and work — what UK patients need to know
Releaf’s own legal-support service data reports that 33 of 114 calls in the first four months of 2026 concerned employment (29%), ahead of criminal-litigation and driving calls. This is a Releaf-specific service dataset, not a UK prevalence estimate.
The ACMD medicinal-cannabis review remains in progress
The ACMD work programme lists its review of cannabis-based products for medicinal use as in progress, with completion expected in summer 2026.
Published NHS figure: 880 identifiable patients — not a UK total
For February 2024 to January 2025, 880 identifiable patients received 5,413 NHS prescription items for licensed cannabis-based medicines in community settings in England.
Rights and law watch
Reviews and official positions without premature conclusions.
Monitoring cards remain monitoring cards until a final primary source supports a real change. Current GreenGuruAI rights guidance remains the practical starting point.
Medical cannabis and work — what UK patients need to know
Releaf’s own legal-support service data reports that 33 of 114 calls in the first four months of 2026 concerned employment (29%), ahead of criminal-litigation and driving calls. This is a Releaf-specific service dataset, not a UK prevalence estimate.
Why this matters
Workplace disputes can involve disability discrimination, reasonable adjustments, drug testing, confidential health data, disciplinary process and role-specific safety duties at the same time. A lawful prescription is important evidence, but it is not a blanket employment exemption.
What changed
GreenGuruAI has published a refreshed employment-rights briefing that separates first-party service data from the official legal foundation, adds a Great Britain/Northern Ireland jurisdiction split and keeps independent employment-solicitor review visibly pending.
What did not change
A prescription does not automatically prevent testing, disciplinary action or safety restrictions; a positive or non-negative test does not by itself prove workplace impairment; and the Equality Act 2010 framework described for Great Britain does not apply unchanged in Northern Ireland.
Primary and official sources
Scoped first-party context data
These links can support a named organisation’s own service statistics or service description. They are not used as the authority for the legal proposition on this card.
The ACMD medicinal-cannabis review remains in progress
The ACMD work programme lists its review of cannabis-based products for medicinal use as in progress, with completion expected in summer 2026.
Why this matters
Recommendations could eventually affect regulation or government policy, but patients should continue to follow current law and official guidance until a final report and government response are published.
What changed
A public call for evidence closed in October 2025 and the ACMD says its working group is analysing the evidence and submissions.
What did not change
This is not a new patient entitlement, prescribing rule or legal defence. GreenGuruAI is not treating an expected publication date as a completed policy change.
Primary and official sources
The current unlicensed-CBPM prescribing framework remains in place during the review
A June 2026 government answer restated that unlicensed CBPMs may be supplied under regulation 167 where the prescriber determines a special clinical need that available licensed medicines cannot meet.
Why this matters
An active review does not itself change who can prescribe, create NHS funding or guarantee access for an individual patient.
What changed
The Government confirmed that the ACMD review is considering the effect of the 2018 legislation and that it will consider recommendations before taking action.
What did not change
No broad new prescribing entitlement, automatic NHS funding route or patient eligibility rule was announced in the answer.
Primary and official sources
Patient access snapshot
Use published figures only within their real scope.
Pulse distinguishes patients from prescription items, licensed medicines from unlicensed CBPMs, NHS activity from private prescribing and England data from a UK total.
Published NHS figure: 880 identifiable patients — not a UK total
For February 2024 to January 2025, 880 identifiable patients received 5,413 NHS prescription items for licensed cannabis-based medicines in community settings in England.
Why this matters
Patient-count claims often combine private estimates, prescription items and different medicine categories. This figure is useful only when its narrow scope remains visible.
What changed
A parliamentary answer published the identifiable-patient and item totals supplied by NHSBSA for licensed medicines such as Epidyolex, nabilone and Sativex.
What did not change
The figure does not represent all UK medical-cannabis patients, private patients, a live national total or a complete count of NHS unlicensed CBPM prescribing.
Primary and official sources
Private prescribing data still cannot support a reliable live patient total
Government says patient information is not routinely collected for private prescriptions. NHSBSA describes controlled-drug reports based on submitted prescribing activity, with important access and coverage limits.
Why this matters
A commercial community size, prescription-item total or clinic estimate should not be relabelled as the number of UK medical-cannabis patients.
What changed
Current NHSBSA documentation confirms that private controlled-drug analysis is available to registered users and is based on prescriptions supplied and submitted to NHS Prescription Services.
What did not change
There is still no official public live total covering every private patient across all four UK nations. Prescriptions not presented, not supplied or not submitted are outside the NHSBSA report described.
Primary and official sources
Medicine verification pulse
Watch catalogue coverage turn into verified medicine intelligence.
GreenGuru currently indexes 20 medicine identities: 2 are in six-claim research and 12 remain discovery-only. Pulse reports evidence progress without turning catalogue presence into an efficacy, suitability, stock or price claim.
Medicine Intelligence · evidence status
Medicine coverage and verification are both visible.
Catalogue presence is not verification. A discovered medicine can be findable before six-claim research starts. Green claim rows require candidate-specific direct product-chain evidence; a whole factual record turns green only after governed human promotion. Clinical/pharmacy review is tracked separately and is never implied by the green factual state.
Pure Sunfarms Pink Kush
Canonical factual medicine record. The six governed source-backed fields have completed human promotion; this does not mean the medicine has been clinically approved or reviewed for patient suitability by GreenGuruAI.
Pure Sunfarms Jet Fuel Gelato
Canonical factual medicine record. The six governed source-backed fields have completed human promotion; this does not mean the medicine has been clinically approved or reviewed for patient suitability by GreenGuruAI.
The Green Organic Dutchman Organic Maple Kush
Canonical factual medicine record. The six governed source-backed fields have completed human promotion; this does not mean the medicine has been clinically approved or reviewed for patient suitability by GreenGuruAI.
The Green Organic Dutchman Organic Cherry Mints
Canonical factual medicine record. The six governed source-backed fields have completed human promotion; this does not mean the medicine has been clinically approved or reviewed for patient suitability by GreenGuruAI.
Pure Sunfarms D. Burger
Canonical factual medicine record. The six governed source-backed fields have completed human promotion; this does not mean the medicine has been clinically approved or reviewed for patient suitability by GreenGuruAI.
The Green Organic Dutchman Organic Gold Butter Mac
Canonical factual medicine record. The six governed source-backed fields have completed human promotion; this does not mean the medicine has been clinically approved or reviewed for patient suitability by GreenGuruAI.
Curaleaf Organic RMY T20 Royal Moby
Afghani Bullrider
Curaleaf Oil [FS] 10mg/ml THC, 10mg/ml CBD (30ml)
Catalogue identity captured. The six-claim research workflow has not started, so product claims remain unverified.
+11 more medicines in the current catalogue. Open Medicines to search the full catalogue and inspect verification state.
Important: Green “factual record verified” means the displayed product facts are supported by the governed source trail and human canonical review. It is not clinical approval, a recommendation or confirmation of current stock or price. “Discovered” or “Not fully verified” describes GreenGuruAI’s evidence state and does not mean a medicine is unsafe, ineffective or unavailable.
Patient experience board
No open submissions in this release.
Patient stories will not be collected simply to fill this section.
A future account would need explicit consent, de-identification, editorial moderation, withdrawal and deletion controls, and a clear separation from verified legal or medical guidance. GreenGuruAI is not currently accepting or storing patient-experience submissions.
Trust labels
Know what kind of claim you are reading.
A current primary source supports the stated change or continuing official position.
A published figure reproduced with its date, geography, methodology and limitations.
A consented, moderated and de-identified account. Lived experience is not evidence of a general rule.
A credible review, consultation or proposal is active, but no final change is claimed.
A visible amendment to a previous GreenGuruAI statement or figure.
Editorial and correction boundary
GreenGuru Pulse is a manually reviewed patient briefing. A monitoring item is not a legal or clinical change, an official figure must not be presented outside its stated scope, and named first-party service data must never be generalised into a national prevalence claim. Legal propositions, confirmed changes and official-data cards must trace to regulated, governmental or other authoritative primary sources under the same sourcing standard used by the Knowledge Centre. Research cards must distinguish human clinical evidence from pre-clinical work, state limitations and avoid turning association into causation. Monitoring items must also identify the primary source for the review, consultation or proposal being watched. A named first-party dataset may appear only as clearly scoped context: it must identify the dataset owner, state the sample or service boundary and must not be used as the authority for a legal claim. Medicine verification progress reports GreenGuru’s evidence state, not efficacy, suitability, current stock or price. Read the editorial policy and corrections process. Pulse contains no sponsored cards, affiliate links, automated legal conclusions or personalised clinical recommendations.